Clinical trials: Inadequate Response
Arthritis, Rheumatoid
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
The purpose of this study is to explore whether LY2127399 is effective in relieving signs and symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or intolerance to at least 1 Tumor Necrosis…
- Trial name
- NCT00689728
- Testing
- LY2127399
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Lupus Erythematosus, Systemic, Lupus Nephritis
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at…
- Trial name
- NCT07015983
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 97 sites in United States, Argentina and 14 more
- Volunteers
- 89 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Diabetic Neuropathy, Painful
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to…
- Trial name
- NCT00385671
- Testing
- duloxetine hydrochloride, pregabalin, gabapentin
- Where
- 9 sites in United States, Germany
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Primary Biliary Cholangitis
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease.
- Trial name
- ELSPIRE (NCT06383403)
- Testing
- Elafibranor
- Where
- 60 sites in United States, Czechia and 8 more
- Volunteers
- 92 people
- Sponsor
- Ipsen
Schizophrenia, Schizoaffective Disorder
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
The purpose of this study is to look at two doses of long-acting injectable risperidone (Risperdal Consta). The study will use a usual dose of Risperdal Consta (50 mg given every two weeks) or a higher dose (75 mg-100 mg given…
- Trial name
- NCT00539071
- Testing
- long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Northwestern University
Rheumatoid Arthritis
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for…
- Trial name
- NCT00124982
- Testing
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Where
- 148 sites in United States, Belgium and 8 more
- Volunteers
- 1,286 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate…
- Trial name
- NCT01457677
- Testing
- RO4995819
- Where
- 92 sites in United States, Austria and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF…
- Trial name
- NCT01592292
- Testing
- Rituximab, Adalimumab, Etanercept
- Where
- 15 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Hand Eczema
Dupilumab in Severe Chronic Hand Eczema
The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.
- Trial name
- DUPSHE (NCT04512339)
- Testing
- Dupilumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
PBC
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
This is a Phase III, randomized, double-blind, multicentre study assessing the efficacy and safety of obecholic acid and Ursodeoxycholic Acid(UDCA) compared with placebo and UDCA in treating of primary biliary cirrhosis (PBC) in…
- Trial name
- NCT06715319
- Testing
- OCA, UDCA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Rheumatoid Arthritis
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs.
- Trial name
- NCT00810277
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Finland
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder that can cause substantial pain and joint tenderness, significant joint damage, and serious disability.
- Trial name
- RA-1 (NCT00221000)
- Testing
- Methoxsalen, Extracorporeal Photopheresis
- Where
- 32 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Mallinckrodt
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436149
- Testing
- SPD489 (Lisdexamfetamine dimesylate )
- Where
- 85 sites in United States, Canada and 4 more
- Volunteers
- 1,262 people
- Sponsor
- Shire
Rheumatoid Arthritis (RA)
Methotrexate - Inadequate Response Device Sub-Study
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
- Trial name
- MTX-IR (NCT01173120)
- Testing
- Abatacept combination product (ACP)
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis, JAK Inhibitor
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response…
- Conditions
- Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound
- Trial name
- TRANSFORM (NCT05090410)
- Testing
- filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Atsushi Kawakami
Rheumatoid Arthritis
ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Adenocorticotrophic Hormone provides safe and effective treatment to induce disease remission in rheumatoid arthritis patients with active disease due to an inadequate response to methotrexate.
- Trial name
- NCT01984268
- Testing
- ACTHAR
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Sepsis, Critical Care
Insufficient Oxygenation in Septic Patients
This study will describe the change of mitochondrial oxygen tension (mitoPO2) compared to traditional parameters of oxygenation and oxygen balance in the first 24 hours of septic patients admitted to the intensive care unit of an…
- Conditions
- Sepsis, Critical Care, Mitochondria, Oxygen
- Trial name
- INOX-SEPSIS (NCT03842722)
- Testing
- Protoporphyrin IX - Triplet State Lifetime Technique
- Where
- Netherlands
- Volunteers
- 81 people
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research